AstraZeneca's blood pressure drug wins US approval

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...
Zacks Investment Research on MSN

AstraZeneca gets FDA nod for new hypertension drug Baxfendy

AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or ...

AstraZeneca Gets U.S. Approval for Hypertension Drug

The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.
Fierce Pharma

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor ...
BioPharma Dive

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...
Fierce Pharma

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure ...

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

AstraZeneca stock falls after FDA panel votes against new cancer drug

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

Broker tips: AstraZeneca, GSK, Oxford Instruments

Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.
Business Wire

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...